An announcement from Palvella Therapeutics ( (PVLA) ) is now available.
On March 31, 2025, Palvella Therapeutics reported its full year 2024 financial results and provided a corporate update, highlighting significant advancements in its clinical programs. The company completed a merger and private placement in December 2024, which facilitated the progression of its QTORIN™ rapamycin into Phase 3 and Phase 2 trials for microcystic lymphatic malformations and cutaneous venous malformations, respectively. These trials could potentially lead to the first FDA-approved therapies for these conditions. Palvella’s financial position, with over $83 million in cash as of December 31, 2024, is expected to support operations into the second half of 2027. The company also announced plans to expand its QTORIN™ platform in 2025, aiming to address additional rare genetic skin diseases.
More about Palvella Therapeutics
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare genetic skin diseases, particularly those without FDA-approved treatments. The company aims to become a leader in the rare disease sector by advancing its late clinical-stage pipeline, including its lead product candidate, QTORIN™ rapamycin.
YTD Price Performance: 134.17%
Average Trading Volume: 62,317
Technical Sentiment Signal: Buy
Current Market Cap: $315.3M
For an in-depth examination of PVLA stock, go to TipRanks’ Stock Analysis page.